Marco Mottinelli

List of Publications by Year
in descending order

18	254	1163117 8	1125743 13
papers	citations	h-index	g-index

18	18	18	315
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy forÎ¼-Opioid Receptor and Opioid-Like Behavioral Effects in Rats. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 410-427.	2.5	52
2	Efficient preparation of an N-aryl Î²-amino acid via asymmetric hydrogenation and direct asymmetric reductive amination en route to Ezetimibe. Tetrahedron: Asymmetry, 2010, 21, 1709-1714.	1.8	37
3	Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain. Frontiers in Pharmacology, 2019, 10, 678.	3.5	31
4	Activity of Mitragyna speciosa (â€œKratomâ€) Alkaloids at Serotonin Receptors. Journal of Medicinal Chemistry, 2021, 64, 13510-13523.	6.4	30
5	Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7331-7336.	2.2	26
6	Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 272-281.	2.5	18
7	Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells. Pathogens, 2021, 10, 1514.	2.8	12
8	Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain. Molecules, 2022, 27, 3617.	3.8	12
9	The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study. Drug Metabolism and Disposition, 2022, 50, 158-167.	3.3	11
10	Accessing simply-substituted 4-hydroxytetrahydroisoquinolines via Pomeranzâ€“Fritschâ€“Bobbitt reaction with non-activated and moderately-activated systems. Beilstein Journal of Organic Chemistry, 2017, 13, 1871-1878.	2.2	8
11	Evaluation of ¹⁸F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue. Theranostics, 2020, 10, 7938-7955.	10.0	7
12	Identification and characterization of MAM03055A: A novel bivalent sigma-2 receptor/TMEM97 ligand with cytotoxic activity. European Journal of Pharmacology, 2021, 906, 174263.	3.5	6
13	Nâ€Phenylâ€1,2,3,4â€tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17Î²â€Hydroxysteroid Dehydrogenase 1 Inhibitors. ChemMedChem, 2021, 16, 259-291.	3.2	4
14	Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1134-1135, 121875.	2.3	0
15	Pharmacological Characterization of Mitragynine: Antinociception, Respiratory Depression, Selfâ€Administration, Drug Discrimination, Tolerance, and withdrawal in Rats. FASEB Journal, 2021, 35, .	0.5	0
16	Effects of Mitragynine and its Active Metabolites on the Reinforcing Effects of Remifentanil and Cocaine in Rats Selfâ€Administering Remifentanil. FASEB Journal, 2022, 36, .	0.5	0
17	Probing the Activity of Mitragyna Speciosa (Kratom) Alkaloids at Serotonin G Proteinâ€Coupled Receptors. FASEB Journal, 2022, 36, .	0.5	0
18	Mitragynine Reverses Paclitaxel Chemotherapyâ€Induced Peripheral Neuropathy and is Mediated via Opioid Receptor Involvement. FASEB Journal, 2022, 36, .	0.5	0